• Anti-ROR1 Antibody (Zilovertamab): Applied Workflows & Assay

  2026-06-09

  Anti-ROR1 Antibody (Zilovertamab) unlocks reliable Wnt5a-induced ROR1 signaling inhibition for ELISA, FACS, and animal model workflows. This guide delivers practical workflow enhancements, troubleshooting insights, and key innovations for cancer and liver injury research.

• Optimizing Myeloma Assays with Pomalidomide (CC-4047): Pract

  2026-06-09

  This article provides scenario-driven, evidence-based guidance for integrating Pomalidomide (CC-4047) (SKU A4212) into hematological malignancy research. Addressing real laboratory questions, it demonstrates how APExBIO’s product supports reproducibility and sensitivity in cell viability and cytokine modulation workflows.

• Molecular Epidemiology and Virulence of C. auris in Guangzho

  2026-06-08

  Wan et al.'s study provides a comprehensive genomic and phenotypic analysis of Candidozyma auris isolates from Guangzhou, delineating clade distribution, antifungal resistance profiles, and virulence factors. These findings deepen understanding of local C. auris epidemiology and offer a scientific basis for infection control strategies.

• S-acylation Regulates NLRP3 Recruitment to the Golgi in Infl

  2026-06-08

  This study reveals that S-acylation of a conserved cysteine residue (Cys-130) in NLRP3 is essential for its recruitment to the Golgi apparatus and subsequent inflammasome activation. The findings provide mechanistic insight into how nigericin-induced Golgi stress modifies NLRP3 acylation dynamics, with implications for controlling inflammatory signaling.

• 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine:

  2026-06-07

  5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine is a highly selective α2-adrenergic receptor agonist used in immune modulation and osteosarcoma recurrence research. Its robust DMSO solubility and high purity enable reproducible receptor signaling assays. Recent studies confirm its immune-mediated, not cytotoxic, anti-tumor effects.

• MMP-2 Responsive Dual-Targeting Liposomes in Breast Cancer I

  2026-06-06

  This study introduces an intelligent, tumor-targeted liposomal delivery system for the sequential release of a PD-1/PD-L1 blockade peptide and an IDO inhibitor in breast cancer. The approach remodels the immunosuppressive microenvironment and demonstrates enhanced efficacy and safety over conventional combination immunotherapies.

• Ibrutinib (PCI-32765) in B-Cell Pathway Dissection: Solubili

  2026-06-05

  Explore the advanced scientific utility of Ibrutinib (PCI-32765) as a selective BTK inhibitor for dissecting B-cell receptor signaling. This article provides unique assay decision guidance, integrating solubility strategies and reference-driven insights to optimize chronic lymphocytic leukemia and autoimmune disease modeling.

• NADPH Oxidase-Derived ROS Activate L-Type Ca2+ Channels in Y

  2026-06-05

  This study demonstrates that reactive oxygen species (ROS) from NADPH oxidase drive arterial contraction in early postnatal rats primarily by activating L-type voltage-gated Ca2+ channels, not via Rho-kinase, PKC, or Src family kinases. These findings clarify the age-dependent mechanisms of vascular tone regulation and suggest new approaches for dissecting redox signaling in developmental physiology.

• MOG (35-55) Peptide: Core Inducer for Autoimmune Encephalomy

  2026-06-04

  MOG (35-55), a myelin oligodendrocyte glycoprotein peptide, is the gold-standard tool for inducing experimental autoimmune encephalomyelitis (EAE) in murine models. Its precise sequence and high encephalitogenicity enable robust modeling of multiple sclerosis and neuroinflammation, facilitating mechanistic and therapeutic research.

• Z-IETD-FMK: Advanced Caspase-8 Inhibition for Immunology Res

  2026-06-04

  Z-IETD-FMK (Benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone) delivers specific, workflow-optimized caspase-8 inhibition for both apoptosis and immune cell activation studies. Leveraging robust solubility protocols, this APExBIO reagent reliably supports T cell proliferation inhibition and NF-κB signaling assays where data reproducibility and mechanistic clarity are critical.

• Mutational Landscape of Myeloma Cell Lines: Pathways and Dru

  2026-06-03

  This article examines a pivotal study that used exome sequencing to map mutations across 30 human multiple myeloma cell lines, revealing both established and novel genetic drivers of tumor progression and drug resistance. The findings provide a vital framework for model selection and therapeutic targeting in hematological malignancy research, with practical implications for preclinical evaluation of agents such as Pomalidomide (CC-4047).

• C34 TLR4 Inhibitor: Precision Modulation of Inflammatory Pat

  2026-06-03

  Explore the scientific foundation and advanced applications of C34, a selective TLR4 inhibitor, in inflammatory signaling research. This article offers profound insight into C34's mechanism and its role in translational models of inflammation.

• Berberine Suppresses SASP in Atherosclerosis via RXRα/PPARγ/

  2026-06-02

  The referenced study reveals that berberine attenuates senescence-associated secretory phenotype (SASP)-driven inflammation in atherosclerosis by activating the RXRα/PPARγ/NEDD4 pathway. This mechanistic insight provides a targeted strategy for addressing chronic vascular inflammation and highlights the significance of macrophage-derived foam cells in mediating disease progression.

• Targeting Glutamine Metabolism in HSCs to Alleviate Liver Fi

  2026-06-02

  This study demonstrates that inhibiting glutamine metabolism in hepatic stellate cells (HSCs), particularly via SIRT4-mediated regulation of glutamate dehydrogenase (GDH), significantly reduces liver fibrosis progression. These findings provide mechanistic insight into metabolic interventions for chronic liver disease and highlight new therapeutic targets for fibrosis reversal.

• AQP9 Downregulation Drives Aggression in KRASG12V Colorectal

  2026-06-01

  This study reveals that KRASG12V-mutated colorectal cancer is marked by pronounced downregulation of aquaporin 9 (AQP9), which correlates with increased tumor proliferation, reduced apoptosis, and greater metastatic potential. Mechanistic insights into the ZHX2–AQP9 axis highlight new therapeutic targets and underscore the need for robust immunodetection methods in translational research.

16073 records 1/1072 page Next 12345 下5页 Last page